Dr. Reddy’s Laboratories announces the launch of Pregabalin Capsules in the U.S. Market

Hyderabad, July 30, 2019:, Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Pregabalin Capsules a therapeutic equivalent generic version of Lyrica^®(pregabalin) Capsules approved by the U.S. Food and Drug Administration (USFDA).

The Lyrica^® (pregabalin) Capsulesbrand had U.S. sales of approximately $5,462 million MAT for the most recent twelve months ending in May 2019 according to IQVIA Health*.

Dr. Reddy’s Pregabalin Capsules are available in 25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg and 300 mg capsules in bottle count sizes of 90. This is also a controlled substance schedule V product.

Lyrica® is a trademark of C.P. PHARMACEUTICALS INTERNATIONAL C.V.

*IQVIA Retail and Non-Retail MAT May 2019.

RDY-0719-257

Corporate Comm India(CCI Newswire)